Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15960853 | 0.78 | GRM1 (0.47) | GRM1MAOBNR3C1AR | |
| SCHEMBL7659766 | 0.78 | GRM1 (0.43) | GRM1MAOBNR3C1AR | |
| SCHEMBL7659762 | 0.78 | GRM1 (0.43) | GRM1MAOBNR3C1AR | |
| SCHEMBL7659771 | 0.78 | GRM1 (0.43) | GRM1MAOBNR3C1AR | |
| SCHEMBL5226865 | 0.75 | LMNA (0.36) | GBA1GABRA1GABRG2GABRB3CYP2D6 | |
| SCHEMBL6770374 | 0.71 | GRM1 (0.73) | GRM1MAOBNR3C1AR | |
| SCHEMBL6770376 | 0.71 | GRM1 (0.73) | GRM1MAOBNR3C1AR | |
| SCHEMBL5227995 | 0.69 | HTR2C (0.37) | GBA1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL30097112 | 0.69 | GBA1 (0.43) | GBA1MAOBCYP2D6SLC6A2SLC6A4 | |
| SCHEMBL12093982 | 0.67 | NR3C1 (0.44) | GBA1NR3C1ARCYP2D6SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1001970-B1 | DIPEPTIDE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUES | PFIZER (US) | 2007-03-07 | — | — | EP | disclosed |
| US-6953791-B2 | Dipeptide derivatives | PFIZER, INC. (US) | 2005-10-11 | — | — | US | disclosed |
| US-6951850-B2 | Dipeptide derivatives | PFIZER, INC. (US) | 2005-10-04 | — | — | US | disclosed |
| US-6924280-B2 | Dipeptide derivatives | PFIZER INC. (US) | 2005-08-02 | — | — | US | disclosed |
| US-RE38524-E1 | Dipeptide derivatives as growth hormone secretagogues | PFIZER INC. | 2004-06-01 | — | — | US | disclosed |
| US-20040009984-A1 | Increasing levels of endogenous growth hormone, especially treating osterporosis, aging frailty or congestive heart failure | CARPINO PHILIP ALBERT (US) | 2004-01-15 | — | — | US | disclosed |
| US-20040006063-A1 | Dipeptide derivatives | CARPINO PHILIP ALBERT (US) | 2004-01-08 | — | — | US | disclosed |
| US-20030216399-A1 | Dipeptide derivatives | CARPINO PHILIP ALBERT (US) | 2003-11-20 | — | — | US | disclosed |
| US-6525047-B2 | Which are growth hormone secretogogues and increase the level of endogenous growth hormone; treating osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair | PFIZER INC. | 2003-02-25 | — | — | US | disclosed |
| US-6432945-B1 | Dipeptide derivatives | PFIZER INC. | 2002-08-13 | — | — | US | disclosed |
| US-6433171-B1 | FOR OSTEOPOROSIS AND/OR FRAILTY, CONGESTIVE HEART FAILURE, FRAILTY ASSOCIATED WITH AGING, OBESITY; ACCELERATING BONE FRACTURE REPAIR, ATTENUATING PROTEIN CATABOLIC RESPONSE AFTER A MAJOR OPERATION, REDUCING CACHEXIA AND PROTEIN LOSS | PFIZER INC. | 2002-08-13 | — | — | US | disclosed |
| US-6429313-B2 | Dipeptide derivatives | PFIZER INC. | 2002-08-06 | — | — | US | disclosed |
| US-20020042415-A1 | Dipeptide derivatives | CARPINO PHILIP ALBERT (US) | 2002-04-11 | — | — | US | disclosed |
| US-20010041703-A1 | Dipeptide derivatives | CARPINO PHILIP ALBERT (US) | 2001-11-15 | — | — | US | disclosed |
| US-6251902-B1 | Dipeptide derivatives as growth hormone secretagogues | PFIZER INC. | 2001-06-26 | — | — | US | disclosed |
| EP-1001970-A1 | DIPEPTIDE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUES | PFIZER INC. (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1998058947-A1 | DIPEPTIDE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUES | PFIZER INC. (US) | 1998-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009984-A1 | Increasing levels of endogenous growth hormone, especially treating osterporosis, aging frailty or congestive heart failure | GHSR, GHRHR, GIPR | GRM1 2707/4885GBA1 2251/4885MAOB 3927/4885 |
| US-20020042415-A1 | Dipeptide derivatives | GIPR, GHRHR, GHSR | GRM1 1222/4885GBA1 3344/4885MAOB 4529/4885 |
| US-20010041703-A1 | Dipeptide derivatives | GIPR, GHRHR, GHSR | GRM1 1317/4885GBA1 3616/4885MAOB 4724/4885 |
| US-20040006063-A1 | Dipeptide derivatives | GIPR, GHRHR, GHSR | GRM1 1575/4885GBA1 3405/4885MAOB 4309/4885 |
| US-20030216399-A1 | Dipeptide derivatives | GIPR, GHRHR, GHSR | GRM1 1222/4885GBA1 3344/4885MAOB 4529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.